Prognostic impact of splenic vessel involvement and tumor size in distal pancreatectomy for adenocarcinoma: a retrospective multicentric cohort study

Gantois, D.; Guilbaud, Théophile; Scemama, Ugo; Girard, Édouard; Picaud, Olivier; Lefèvre, Marine; Elgani, Myriam; Hamidou, Zeinab; Moutardier, Vincent; Balandraud, Paul; Chirica, Mircea; Barbier, Louise; Fuks, David; Birnbaum, David

doi:10.1007/s00423-021-02291-w

Cited by 6 publications

(3 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several poor prognostic factors have been reported for pancreatic body or tail cancer [4][5][6]. SpV involvement has been highlighted as a speci c factor for pancreatic body or tail cancer.…”

Section: Discussionmentioning

confidence: 99%

“…A negative survival impact of pathological splenic vessel involvement in pancreatic body or tail cancer [9], especially with respect to SpA involvement [5,[10][11][12][13][14], has been reported. In our study, SpV invasion and tumour size, but not SpA invasion, were identi ed as independent prognostic factors, consistent with previous literature [15,16].…”

Section: Discussionmentioning

confidence: 99%

“…However, in pancreatic body or tail cancer, the involvement of these vessels is not surgically signi cant but is a poor prognostic factor in oncology, along with lymph node metastasis, tumour size, and tumour differentiation [4][5][6]. Although there have been several studies on splenic vessel involvement [5,[7][8][9], especially on SpA involvement [10][11][12][13][14], few studies have focused on SpV involvement [15,16].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Impact of radiological and pathological splenic vein involvement in patients with resectable pancreatic body or tail cancer

Kuriyama,

Mizuno,

Sakamoto

et al. 2024

Langenbecks Arch Surg

View full text Add to dashboard Cite

Several studies have reported a negative impact on survival associated with splenic vessel involvement, especially splenic artery (SpA) involvement, in patients diagnosed with pancreatic body or tail cancer.However, there is limited research on splenic vein (SpV) involvement. Therefore, we aimed to elucidate the signi cance of splenic vessel involvement, especially SpV involvement, in patients with resectable pancreatic body or tail cancer. MethodsBetween January 2007 and December 2021, 116 consecutive patients underwent distal pancreatectomies for pancreatic body or tail cancer. Among them, this study speci cally examined 88 patients with resectable pancreatic body or tail cancer to elucidate prognostic factors using a multivariable Cox proportional analysis. The Kaplan-Meier method evaluated the impact of SpV involvement in terms of both radiological and pathological aspects and the e cacy of neoadjuvant therapy. ResultsHigher pre-operative carcinoembryonic antigen levels, larger tumour size, pathological SpV invasion, and non-completion of adjuvant therapy were identi ed as independent poor prognostic factors for overall survival (OS) and recurrence-free survival (RFS). Additionally, patients with radiological SpV encasement had signi cantly worse prognoses in terms of OS (p = 0.039) and RFS (p < 0.001). The sensitivity and speci city of multidetector-row computed tomography for detecting pathological SpV invasion were 81.0% and 61.2%, respectively. However, the prognostic impact of neoadjuvant therapy could not be determined, regardless of radiological SpV involvement. ConclusionRadiological and pathological SpV involvement is a poor prognostic factor for patients with resectable pancreatic body or tail cancer. New innovative treatments and effective neoadjuvant therapy regimens are required for patients with SpV involvement.

show abstract

Section: Discussionmentioning

confidence: 99%